https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2026-03-23 16:02:092026-03-23 16:20:37CYGNOS BioTech Awarded U.S. Department of Defense SBIR Phase II Contract
https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2026-01-05 18:03:122026-03-23 16:22:11CYGNOS BioTech, LLC Selected for U.S. Department of Defense SBIR Phase II Negotiation to Advance Broad-Spectrum Antiviral Platform
https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2025-07-08 21:06:392026-03-23 16:08:52CYGNOS BioTech to Present Innovative PVX Antiviral Platform at U.S. DoD and International Scientific Conference
https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2025-04-21 15:04:032026-03-23 16:08:39CYGNOS BioTech Awarded Contract to Develop Critical Antiviral Drug Amid New and Emerging Viral Disease Threats
CYGNOS BioTech Awarded U.S. Department of Defense SBIR Phase II Contract
CYGNOS BioTech, LLC Selected for U.S. Department of Defense SBIR Phase II Negotiation to Advance Broad-Spectrum Antiviral Platform
CYGNOS BioTech to Present Innovative PVX Antiviral Platform at U.S. DoD and International Scientific Conference
CYGNOS BioTech Awarded Contract to Develop Critical Antiviral Drug Amid New and Emerging Viral Disease Threats